LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 9, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company has been awarded a dual-source group purchasing

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 5, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 31, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the appointment of Karen Licitra to its board of directors as a

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 23, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, will

Fiscal 2019 Fourth Quarter Highlights Net sales of $96.3 million , an increase of 9.0% year over year and 5.2% organically Gross margin of 53.6%, flat year-over-year GAAP EPS of $1.54 per share; adjusted EPS of $0.25 per share Completed sale of NAMIC Fluid Management business to Medline Industries

LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 20, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and

LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 4, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, will

LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 3, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it closed the previously announced sale of its NAMIC ® fluid

LATHAM, N.Y. --(BUSINESS WIRE)--May 28, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that representatives of the Company will ring the NASDAQ Stock

LATHAM, N.Y. --(BUSINESS WIRE)--May 22, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the United States Food and Drug Administration ( FDA )

LATHAM, N.Y. --(BUSINESS WIRE)--May 13, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced enrollment of the first patient in its NanoKnife ® Irreversible

AngioDynamics to host conference call today at 5:00 p.m. ET LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 17, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for oncology, vascular access, and peripheral vascular disease, today announced that

LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 17, 2019-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company received central Institutional Review Board (IRB)

Fiscal 2019 Third Quarter Highlights Net sales of $86.3 million , an increase of 3.0% year over year Gross margin declined 10 basis points year over year to 54.1% GAAP EPS of $0.02 per share; adjusted EPS of $0.19 per share Cash provided by operations of $8.3 million ; capital expenditures of $0.9

LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 1, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner , Executive Vice President and Chief

LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 1, 2019-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States Food and Drug Administration ( FDA ) approved

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 28, 2019-- Second paragraph, first sentence of release should read: The additional indications clear the OARtrac System for use with patient-specific, pre-calibrated Plastic Scintillating Detector (PSD) sensors used during cancer treatments to measure photon and

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 12, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 8, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States District Court for the District of Delaware ,

LATHAM, N.Y. --(BUSINESS WIRE)--Feb. 26, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and